US Patent Issued to NOVMETAPHARMA on June 30 for "Use of composition for enhancing anticancer effect, comprising ERRy inhibitor as active ingredient" (South Korean Inventors)

ALEXANDRIA, Va., July 16 -- United States Patent no. 12,667,565, issued on June 30, was assigned to NOVMETAPHARMA Co. LTD. (Seoul, South Korea).

"Use of composition for enhancing anticancer effect, comprising ERRy inhibitor as active ingredient" was invented by Keun Gyu Park (Daegu, South Korea), In Kyu Lee (Daegu, South Korea), Sung Jin Cho (Daegu, South Korea), Yeon Kyung Choi (Daegu, South Korea), Mi Jin Kim (Daegu, South Korea), Jung Wook Chin (Daegu, South Korea), Yong Hyun Jeon (Daegu, South Korea), Jin A Kim (Daegu, South Korea), Dong Su Kim (Daegu, South Korea) and Hoe Yune Jung (Pohang-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a pharmaceutical co...